EA201400064A1 - Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб - Google Patents

Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб

Info

Publication number
EA201400064A1
EA201400064A1 EA201400064A EA201400064A EA201400064A1 EA 201400064 A1 EA201400064 A1 EA 201400064A1 EA 201400064 A EA201400064 A EA 201400064A EA 201400064 A EA201400064 A EA 201400064A EA 201400064 A1 EA201400064 A1 EA 201400064A1
Authority
EA
Eurasian Patent Office
Prior art keywords
regoraphenib
pharmaceutical composition
ophthalmic pharmaceutical
local application
ophthalmic
Prior art date
Application number
EA201400064A
Other languages
English (en)
Inventor
Михаэль Бёттгер
Жорж Фон-Дегенфельд
Юлия Фройндлиб
Клаудиа Хирт-Дитрих
Йёрг Кельдених
Йюрген Клар
Уве Мюнстер
Андреас Ом
Аннетт Рихтер
Бернд Ридль
Original Assignee
Байер Хелфкеэ Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46456546&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201400064(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Байер Хелфкеэ Ллк filed Critical Байер Хелфкеэ Ллк
Publication of EA201400064A1 publication Critical patent/EA201400064A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts

Abstract

Настоящее изобретение относится к офтальмологическим фармацевтическим композициям для местного применения, которые содержат регорафениб, гидрат, сольват или его фармацевтически приемлемую соль или их полиморф, а также процесс их получения для использования при лечении офтальмологических расстройств.
EA201400064A 2011-06-28 2012-06-26 Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб EA201400064A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11171719 2011-06-28
EP12155281 2012-02-14
PCT/EP2012/062365 WO2013000917A1 (en) 2011-06-28 2012-06-26 Topical ophthalmological pharmaceutical composition containing regorafenib

Publications (1)

Publication Number Publication Date
EA201400064A1 true EA201400064A1 (ru) 2014-05-30

Family

ID=46456546

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400064A EA201400064A1 (ru) 2011-06-28 2012-06-26 Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб

Country Status (25)

Country Link
US (1) US20140296301A1 (ru)
EP (1) EP2726059A1 (ru)
JP (1) JP5998213B2 (ru)
KR (1) KR20140048218A (ru)
CN (1) CN103889399A (ru)
AP (1) AP2013007335A0 (ru)
AR (1) AR086800A1 (ru)
AU (1) AU2012277905A1 (ru)
BR (1) BR112013033831A2 (ru)
CA (1) CA2840329A1 (ru)
CL (1) CL2013003700A1 (ru)
CO (1) CO6920289A2 (ru)
CR (1) CR20130693A (ru)
CU (1) CU24163B1 (ru)
DO (1) DOP2013000314A (ru)
EA (1) EA201400064A1 (ru)
EC (1) ECSP13013106A (ru)
GT (1) GT201300322A (ru)
HK (1) HK1197176A1 (ru)
MX (1) MX2013015287A (ru)
PE (1) PE20141031A1 (ru)
TN (1) TN2013000533A1 (ru)
UY (1) UY34166A (ru)
WO (1) WO2013000917A1 (ru)
ZA (1) ZA201400646B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877933B2 (en) 2004-09-29 2014-11-04 Bayer Intellectual Property Gmbh Thermodynamically stable form of a tosylate salt
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
UY35183A (es) * 2012-12-21 2014-07-31 Bayer Healthcare Llc Composición farmacéutica oftalmológica tópica que contiene regorafenib
WO2015011659A1 (en) * 2013-07-24 2015-01-29 Dr. Reddys Laboratories Limited Crystalline polymorphic forms of regorafenib and processes for the preparation of polymorph i of regorafenib
CN103923000A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
CN104546776B (zh) * 2015-02-10 2017-08-22 杭州朱养心药业有限公司 瑞戈非尼片剂药物组合物和制法
KR20240034866A (ko) * 2015-06-06 2024-03-14 클라우드브레이크 테라퓨틱스, 엘엘씨 익상편을 치료하기 위한 조성물 및 방법
CA3026118A1 (en) 2016-06-02 2017-12-07 Cloudbreak Therapeutics, Llc Compositions and methods of using nintedanib for treating ocular diseases with abnormal neovascularization

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2732222B1 (fr) * 1995-03-28 1997-04-25 Oreal Utilisation d'un antagoniste de cgrp pour le traitement des prurits et des dysesthesies oculaires et palpebraux
JP2005529928A (ja) * 2002-05-28 2005-10-06 アルタナ　ファルマ　アクチエンゲゼルシャフト 眼の病気を治療するためのロフルミラストの眼科的使用
CL2004001834A1 (es) * 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
ZA200709251B (en) 2005-05-10 2009-08-26 Alcon Inc Suspension formulations comprising an active principle, a poloxamer or meroxapol surfactant and a glycol, its use for the manufacture of a medicament for treating ophthalmic disorders
JP2008543775A (ja) 2005-06-08 2008-12-04 ターゲジェン インコーポレーティッド 眼の障害を治療するための方法および組成物
SI1968594T1 (sl) 2005-11-29 2011-01-31 Glaxosmithkline Llc Tretma okularnih neovaskularnih motenj, kot makularne degeneracije, angiodnih prog. uveitisa in makularnega edema
EP1962828A1 (en) * 2005-12-15 2008-09-03 Bayer HealthCare AG Diaryl urea for treating inflammatory skin, eye and/or ear diseases
EP1962803A1 (en) 2005-12-23 2008-09-03 Alcon, Inc. PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
KR20100016270A (ko) * 2007-05-11 2010-02-12 산텐 세이야꾸 가부시키가이샤 비맥각계의 선택적 ｄ2 수용체 작용제를 유효 성분으로서 함유하는 후안부 질환의 예방 또는 치료제
DE102007055341A1 (de) * 2007-11-19 2009-05-20 Bayer Animal Health Gmbh Stabilisierung öliger Suspensionen enthaltend hydrophobe Kieselsäuren
WO2010127029A1 (en) 2009-05-01 2010-11-04 Ophthotech Corporation Methods for treating or preventing ophthalmological diseases
BR112012001030A2 (pt) 2009-07-16 2019-09-24 Glaxo Wellcome Mfg Pte Ltd método para tratar a degeneração macular, e, uso de um composto.

Also Published As

Publication number Publication date
TN2013000533A1 (en) 2015-03-30
PE20141031A1 (es) 2014-08-21
CO6920289A2 (es) 2014-04-10
AU2012277905A1 (en) 2014-01-16
CA2840329A1 (en) 2013-01-03
ZA201400646B (en) 2015-11-25
BR112013033831A2 (pt) 2017-02-14
AP2013007335A0 (en) 2013-12-31
CN103889399A (zh) 2014-06-25
HK1197176A1 (en) 2015-01-09
UY34166A (es) 2013-01-31
JP5998213B2 (ja) 2016-09-28
EP2726059A1 (en) 2014-05-07
CL2013003700A1 (es) 2014-07-18
NZ619229A (en) 2016-04-29
KR20140048218A (ko) 2014-04-23
GT201300322A (es) 2014-11-13
US20140296301A1 (en) 2014-10-02
ECSP13013106A (es) 2014-01-31
CR20130693A (es) 2016-05-02
AU2012277905A8 (en) 2014-01-30
CU20130168A7 (es) 2014-04-24
WO2013000917A1 (en) 2013-01-03
CU24163B1 (es) 2016-03-31
MX2013015287A (es) 2014-03-31
DOP2013000314A (es) 2014-04-15
AR086800A1 (es) 2014-01-22
JP2014518233A (ja) 2014-07-28

Similar Documents

Publication Publication Date Title
EA201592250A1 (ru) Пиразолопирролидиновые производные и их применение в лечение заболеваний
EA201590520A1 (ru) Фармацевтическая композиция с покрытием, содержащая регорафениб
EA201400064A1 (ru) Офтальмологическая фармацевтическая композиция для местного применения, которая содержит регорафениб
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201490864A1 (ru) Производные (4-фенилимидазол-2-ил)этиламина в качестве модуляторов натриевых каналов
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
UA111588C2 (uk) Композиція інгібітора jak для місцевого застосування
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201492287A1 (ru) Дейтерированные производные руксолитиниба
WO2013188273A8 (en) Topical ophthalmological pharmaceutical composition containing axitinib
EA201592254A1 (ru) Производные пиразолопирролидин-4-она и их применение при лечении заболевания
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
WO2013188283A8 (en) Topical ophthalmological pharmaceutical composition containing sunitinib
EA201490573A1 (ru) Соединение бензотиазолона
IN2013DN02555A (ru)
TN2015000280A1 (en) Topical Ophthalmological Pharmaceutical Composition containing Regorafenib
WO2013188279A8 (en) Topical ophthalmological pharmaceutical composition containing cediranib
EA200802000A1 (ru) Фармацевтически приемлемые соли и полиморфные формы
DOP2015000049A (es) Composición farmacéutica recubierta que contiene regorafenib
UA111851C2 (uk) Сполуки піридазинону та їх використання як інгібіторів daao